Literature DB >> 29286591

Repeated Low-Grade Infections Predict Antidepressant-Resistant Depression: A Nationwide Population-Based Cohort Study.

Jia-Shyun Jeng1, Cheng-Ta Li2,1,3, Mu-Hong Chen1,3, Wei-Chen Lin1,3, Ya-Mei Bai1,3, Shih-Jen Tsai1,3, Tung-Ping Su1,3, Wen-Hang Chang1, Yen-Jen Sung4,5,6.   

Abstract

BACKGROUND: The relationship between severe inflammation and clinical depression in the context of major medical illnesses has been addressed, but the relationship between inflammation caused by mild infections and clinical depression is unclear. We aimed to examine whether a history of repeated low-grade infections (RLGI) in medically healthy subjects (MHS) could increase their vulnerability to major depressive disorder (MDD) (ICD-9-CM) and whether RLGI could be associated with higher resistance to antidepressants in those developing MDD.
METHOD: A nationwide, population-based cohort study (January 1996 to December 2011) was conducted for MHS with and without a history of RLGI. The rates of MDD during an up to 8-year follow-up period were compared between the 2 groups in 2 independent cohorts. The stratified responses to adequate antidepressant trials, including easy-to-treat (ETT) and difficult-to-treat (DTT) responses, were also compared in the MDD patients.
RESULTS: During the follow-up, the 2 cohorts consistently revealed that the RLGI(+) (ie, high-inflammation; n = 727) group had a significantly higher chance of developing MDD over time than the RLGI(-) (ie, low-inflammation; n = 443) group: Cox proportional hazards regression models showed that the hazard ratio associated with a history of RLGI was 1.369 to 1.911 (P < .001), after adjusting for confounding factors. The RLGI(+) group was consistently associated with a higher likelihood of DTT responses than was the RLGI(-) group (Cohort-2002: 11.5% vs 7.6%; Cohort-2004: 11.8% vs 4.3%; P < .05 by Wald χ² tests in both cohorts).
CONCLUSIONS: This is the first large-scale retrospective cohort study to report a reliable temporal association between a history of RLGI and subsequent diagnosis of MDD and poor responses to antidepressants in 2 independent cohorts. Our data support the view that repeated mild infections play a role in the pathophysiology of MDD and antidepressant-resistant depression. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29286591     DOI: 10.4088/JCP.17m11540

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  DNA methylation studies of depression with onset in the peripartum: A critical systematic review.

Authors:  Sarah Ellen Braun; Dana Lapato; Roy E Brown; Eva Lancaster; Timothy P York; Ananda B Amstadter; Patricia A Kinser
Journal:  Neurosci Biobehav Rev       Date:  2019-04-11       Impact factor: 8.989

2.  Baseline Pro-Inflammatory Cytokine Levels Moderate Psychological Inflexibility in Behavioral Treatment for Chronic Pain.

Authors:  Bianka Karshikoff; Jenny Åström; Linda Holmström; Mats Lekander; Mike K Kemani; Rikard K Wicksell
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

3.  Allostatic load in the association of depressive symptoms with incident coronary heart disease: The Jackson Heart Study.

Authors:  Shannon L Gillespie; Cindy M Anderson; Songzhu Zhao; Yubo Tan; David Kline; Guy Brock; James Odei; Emily O'Brien; Mario Sims; Sophie A Lazarus; Darryl B Hood; Karen Patricia Williams; Joshua J Joseph
Journal:  Psychoneuroendocrinology       Date:  2019-07-04       Impact factor: 4.905

4.  DNA methylation associated with postpartum depressive symptoms overlaps findings from a genome-wide association meta-analysis of depression.

Authors:  Dana M Lapato; Roxann Roberson-Nay; Robert M Kirkpatrick; Bradley T Webb; Timothy P York; Patricia A Kinser
Journal:  Clin Epigenetics       Date:  2019-11-28       Impact factor: 6.551

5.  The association between C-reactive protein, mood disorder, and cognitive function in UK Biobank.

Authors:  David C Milton; Joey Ward; Emilia Ward; Donald M Lyall; Rona J Strawbridge; Daniel J Smith; Breda Cullen
Journal:  Eur Psychiatry       Date:  2021-02-01       Impact factor: 5.361

6.  Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression- an Asian Sub-group Analysis from the SUSTAIN-2 Study.

Authors:  Hong Jin Jeon; Po-Chung Ju; Ahmad Hatim Sulaiman; Salina Abdul Aziz; Jong-Woo Paik; Wilson Tan; Daisy Bai; Cheng-Ta Li
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-02-28       Impact factor: 2.582

7.  Relationship Between Blood Cytokine Levels, Psychological Comorbidity, and Widespreadness of Pain in Chronic Pelvic Pain.

Authors:  Bianka Karshikoff; Katherine T Martucci; Sean Mackey
Journal:  Front Psychiatry       Date:  2021-06-25       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.